Please refer to ClinicalTrials.gov : NCT02864953.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224029

Enrollment

768

Registered

2018-08-31

Start date

2019-03-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Large Hemispheric Infarction

Interventions

investigational material(s) Generic name etc : INN of investigational material : Glibenclamide Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Please refer to ClinicalTrials.gov : NCT02864953.

Exclusion criteria

Exclusion criteria: Please refer to ClinicalTrials.gov : NCT02864953.

Design outcomes

Primary

Measure	Time frame
efficacy	—

Secondary

Measure	Time frame
safety efficacy	—

Countries

Asia except Japan, Europe, Japan, North America, Oceania, South America

Contacts

Public ContactBiogen Japan Medical Information

Biogen Japan Ltd.

japan-medinfo@biogen.com+81-120-560-086

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026